JP2019512535A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512535A5
JP2019512535A5 JP2018551351A JP2018551351A JP2019512535A5 JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5 JP 2018551351 A JP2018551351 A JP 2018551351A JP 2018551351 A JP2018551351 A JP 2018551351A JP 2019512535 A5 JP2019512535 A5 JP 2019512535A5
Authority
JP
Japan
Prior art keywords
disorders
compound
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018551351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512535A (ja
JP6968092B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/057765 external-priority patent/WO2017167993A1/en
Publication of JP2019512535A publication Critical patent/JP2019512535A/ja
Publication of JP2019512535A5 publication Critical patent/JP2019512535A5/ja
Application granted granted Critical
Publication of JP6968092B2 publication Critical patent/JP6968092B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018551351A 2016-04-01 2017-03-31 Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体 Active JP6968092B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163571.9 2016-04-01
EP16163571 2016-04-01
PCT/EP2017/057765 WO2017167993A1 (en) 2016-04-01 2017-03-31 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (3)

Publication Number Publication Date
JP2019512535A JP2019512535A (ja) 2019-05-16
JP2019512535A5 true JP2019512535A5 (enExample) 2020-04-23
JP6968092B2 JP6968092B2 (ja) 2021-11-17

Family

ID=55650321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551351A Active JP6968092B2 (ja) 2016-04-01 2017-03-31 Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Country Status (8)

Country Link
US (1) US10669286B2 (enExample)
EP (1) EP3436459B1 (enExample)
JP (1) JP6968092B2 (enExample)
CN (1) CN109195969B (enExample)
BR (1) BR112018069936A2 (enExample)
CA (1) CA3019026A1 (enExample)
EA (1) EA201892153A1 (enExample)
WO (1) WO2017167993A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN108137547B (zh) 2015-08-03 2021-11-12 百时美施贵宝公司 可用作TNFα调节剂的杂环化合物
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN108948034B (zh) * 2018-06-05 2019-09-13 河南大学 一种色满桥环异吲哚酮及其制备方法
WO2020084008A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) * 2023-01-05 2024-07-11 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
TW202521544A (zh) * 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途
WO2025212627A1 (en) * 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408477A (pt) 2003-03-10 2006-04-04 Pfizer compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN103702994B (zh) 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
TR201807207T4 (tr) * 2012-06-11 2018-06-21 Ucb Biopharma Sprl Tnf-alfa modüle edici benzimidazol bileşikleri.
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016050975A1 (en) 2014-10-03 2016-04-07 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives

Similar Documents

Publication Publication Date Title
JP2019512535A5 (enExample)
JP2019512533A5 (enExample)
JP2014513139A5 (enExample)
JP2017531648A5 (enExample)
JP2016040288A5 (enExample)
JP2014513110A5 (enExample)
JP2016520618A5 (enExample)
JP2014139226A5 (enExample)
JP2013510124A5 (enExample)
JP2016525075A5 (enExample)
JP2014525420A5 (enExample)
JP2015143283A5 (enExample)
JP2018501315A5 (enExample)
JP2014513140A5 (enExample)
ME02203B (me) Hinolin i hinoksalin derivati kao inhibitori kinaza
JP2013529611A5 (enExample)
JP2012525431A5 (enExample)
JP2016525076A5 (enExample)
JP2016523270A5 (enExample)
JP2016522232A5 (enExample)
HRP20201094T1 (hr) IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA
JP2013540712A5 (enExample)
JP2016520118A5 (enExample)
JP2017532360A5 (enExample)
JP2014510147A5 (enExample)